📰 3 sources covering this story

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

First covered 1 days ago · latest take 39 mins ago. Compare how each outlet is covering it — and rate the sources you trust.

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
CNBC
CNBC39 mins ago
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
Global News
Global News19 hrs ago
GLP-1 drugs are driving higher sales for Eli Lilly and Novo Nordisk
Sales of Mounjaro, Eli Lilly’s diabetes drug, rose 91 per cent in the second quarter of the year to US$9.94 billion, well above analysts' expectations.
Reuters
Reuters🏁 first to report1 days ago
Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk
Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk  Reuters
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →